Prostate Cancer

February 18th 2025

Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.

February 17th 2025

Olaparib plus abiraterone improved radiographic PFS and overall survival in mCRPC patients with germline or somatic BRCA mutations vs placebo plus abiraterone.

February 14th 2025

Patients who did not receive fish oil experienced a Ki-67 index increase of 24% vs the 15% Ki-67 index decrease for patients with a low omega-6, high omega-3 diet who received fish oil.

February 13th 2025

The ARANOTE phase 3 trial showed darolutamide plus ADT improved outcomes in mHSPC regardless of disease volume.